908 Devices (MASS) to Release Quarterly Earnings on Tuesday

Key Points

• 908 Devices is set to release its Q2 2025 earnings data on Tuesday, August 5th, with analysts expecting a loss of ($0.16) per share and revenue of $12.17 million.
• In the previous earnings report, 908 Devices reported ($0.22) EPS, surpassing expectations but showing a negative net margin of 28.80%.
• Analysts have given the stock a consensus rating of "Moderate Buy", with a price target of $5.33, despite a recent “sell” rating from Weiss Ratings.

908 Devices (NASDAQ:MASS - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $12.17 million for the quarter. 908 Devices has set its FY 2025 guidance at EPS.

908 Devices (NASDAQ:MASS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $11.78 million during the quarter, compared to analyst estimates of $11.90 million. 908 Devices had a negative net margin of 28.80% and a negative return on equity of 27.10%. On average, analysts expect 908 Devices to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

908 Devices Stock Performance

NASDAQ:MASS traded down $0.13 on Friday, hitting $6.42. The stock had a trading volume of 287,651 shares, compared to its average volume of 266,470. The stock has a market cap of $230.22 million, a P/E ratio of -11.89 and a beta of 0.37. 908 Devices has a 1 year low of $1.81 and a 1 year high of $8.06. The firm's fifty day simple moving average is $6.79 and its two-hundred day simple moving average is $4.83.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of 908 Devices in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.

Insider Activity

In related news, insider Michael S. Turner sold 16,082 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $7.51, for a total value of $120,775.82. Following the completion of the transaction, the insider directly owned 8,521 shares of the company's stock, valued at approximately $63,992.71. This trade represents a 65.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joseph H. Iv Griffith sold 6,940 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $7.08, for a total transaction of $49,135.20. Following the completion of the transaction, the chief financial officer directly owned 102,930 shares of the company's stock, valued at approximately $728,744.40. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,543 shares of company stock valued at $233,890 in the last three months. Company insiders own 23.70% of the company's stock.

Institutional Trading of 908 Devices

A hedge fund recently bought a new stake in 908 Devices stock. AQR Capital Management LLC acquired a new stake in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 81,558 shares of the company's stock, valued at approximately $365,000. AQR Capital Management LLC owned approximately 0.23% of 908 Devices as of its most recent filing with the SEC. Hedge funds and other institutional investors own 88.06% of the company's stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.